Oncology Central

Considerations on the prognostic and predictive significance of HLA-G in breast cancer


The higher incidence of breast cancer in developed countries has been tempered by reductions in mortality, largely attributable to screening programs, improved surgery, and advances in preoperative and adjuvant systemic therapy. Decisions regarding use of systemic therapy in early breast cancer patients are mainly based on prognostic and predictive factors like lymph node status and tumor status regarding size, grade, and hormone receptor and HER2 expression [1]. However, the currently used prognostic factors do not provide optimal risk-stratification. The goals of personalized medicine and targeted therapy demand further information regarding residual disease risk and potential benefit of additional treatments in specific circumstances.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.